For this purpose, the breast cancer cell lines, MCF-7 and ZR-75-1 were treated with compounds such as macrolide antibiotic rifampicin; which is a human selective SXR activator [10], the anti-estrogen tamoxifen; which is also an SXR agonist [14,40], the fatty acid ethanolamide anandamide, the anti-fungal clotrimazole [41] or the calcium channel blocker nifedipine [42]. This evidence concerns the gene NR1I2 and breast cancer.